SCHEMBL7592084

SCHEMBL7592084

CCn1c2ccccc2c2cc(C=CC(=O)c3cc(OC)ccc3OC)ccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.61
PDE4A P27815 1/20 0.60
PDE4B Q07343 1/20 0.60
PDE4C Q08493 1/20 0.60
PDE4D Q08499 1/20 0.60
PTGER4 P35408 1/20 0.53
SRC P12931 2/20 0.51
MAPT P10636 2/20 0.51
ABCB1 P08183 1/20 0.50
ABCC1 P33527 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7591205 0.92 ABCG2 (0.61) ABCG2PTGER4SRCMAPTABCB1
SCHEMBL16066037 0.90 ABCG2 (0.60) ABCG2SRCMAPTABCB1ABCC1
SCHEMBL7588254 0.90 ABCG2 (0.60) ABCG2SRCMAPTABCB1ABCC1
SCHEMBL25193173 0.88 ABCG2 (0.60) ABCG2MAPTMEN1ALDH1A1MAPK1
SCHEMBL7594011 0.82 KDM4E (0.62) ABCG2SRCMAPTABCB1MEN1
SCHEMBL30274993 0.81 F3 (0.55) ABCG2PTGER4SRCMAPTMEN1
SCHEMBL29003694 0.81 F3 (0.55) ABCG2PTGER4SRCMAPTMEN1
SCHEMBL7592082 0.80 ABCG2 (0.61) ABCG2PDE4APDE4BPDE4CPDE4D
SCHEMBL25206045 0.80 KDM4E (0.55) ABCG2SRCMAPTMEN1ALDH1A1
SCHEMBL30383583 0.80 KDM4E (0.55) ABCG2SRCMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253141-A1 Substituted carbazoles as tubulin polymerization inhibitors and their use for the treatment of cancer Aventis Pharma S.A. (FR) 2002-10-30 EP disclosed